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Mitochondrial intermembrane spacet neutral cystein proteases, are involved in a variety of cellular processes. We have
previously shown the characteristics of mitochondrial μ-calpain even though calpastatin, a speciﬁc
endogenous inhibitor of cytosolic calpains, was not present in the mitochondria. This suggested that the
regulatory system of mitochondrial calpains differs from that of cytosolic calpains, and endogenous regulatory
molecule(s) must exist in the mitochondria. In this study, we have identiﬁed ERp57 in partially puriﬁed
mitochondrial μ-calpain using peptide mass ﬁngerprinting based onMALDI-TOFMS. ERp57 is a member of the
protein-disulﬁde isomerase (PDI) family and functions as a molecular chaperone within the ER. We showed
that ERp57 was present in the mitochondria and was associated with mitochondrial μ-calpain. PDI inhibitors,
such as DTNB and PAO, caused a degradation of the mitochondrial μ-calpain large subunit. The release of
apoptosis-inducing factor (AIF) from the mitochondrial inner membrane was inhibited by treatment of the
isolated mitochondria with DTNB and immunoprecipitation of ERp57-associated mitochondrial μ-calpain.
Mitochondrial μ-calpain band in casein zymography disappeared by treatment with anti-ERp57 antibody. Our
results demonstrate that ERp57 forms complexes with mitochondrial μ-calpain, and ERp57-associated
mitochondrial μ-calpain cleaves AIF to a truncated form.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionCalpains (EC 3.4.22.17) are calcium-dependent neutral cystein pro-
teases that catalyze the endoproteolytic cleavage of speciﬁc substrates
and are involved in a variety of cellular processes [1–3]. The calpain
family can be classiﬁed as typical calpains, and are further divided into
ubiquitous and tissue-speciﬁc calpains and atypical calpains [4–6].
Two major ubiquitous calpains, viz., μ-calpain and m-calpain (mo-
lecular mass, ~80 kDa), are associated with a common regulatory
small subunit (molecular mass, ~30 kDa) [7]. These two calpains have
a speciﬁc endogenous inhibitor, calpastatin [8–11].
The results of earlier studies demonstrated that; calpain-like ac-
tivities were present in isolated mitochondria [12–16], cytosolic μ-
calpain translocates into mitochondria [17–19], and μ-calpain exists in
mitochondria of normal rat cortex and human neuroblastoma cells
[20]. In addition, three calpain 10 splice variants are present in the
kidney mitochondrial matrix of many different species of animals
[21,22]. We have examined the characteristics of speciﬁc mitochon-yacrylamide gel electrophoresis
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l rights reserved.drial calpains and found two types of mitochondrial calpains by casein
zymography; mitochondrial μ-calpain and an unknownmitochondrial
calpain [23]. In a previous study, we found that many of the charac-
teristics of mitochondrial μ-calpain and cytosolic μ-calpain are similar
but calpastatin was not present in the mitochondria.
An association between calpain and calpastatin can occur in the
cytoplasm in the presence of physiological levels of Ca2+ [24]. Con-
formational modiﬁcation to the active calpain form is regulated by
calpastatin [2]. The biologic environment in the cytoplasm is very
different from that in the mitochondria (pHs, Ca2+ concentrations,
membrane structures). The inﬂux and efﬂux of Ca2+ in mitochondria
occur through the outer and inner membranes, suggesting that the
mitochondrial environment is qualiﬁed for calpain activation. Because
of these characteristics, we expected that unique regulation mechan-
isms of mitochondrial calpains existed in mitochondria, and have
suggested that mitochondrial calpains are associated with unidenti-
ﬁed regulatory molecules.
We have partially puriﬁed mitochondrial μ-calpain from rat liver
mitochondria, and used peptide mass ﬁngerprinting (PMF) based on
MALDI-TOFMS to identify the proteins associated with mitochondrial
μ-calpain. ERp57 (molecular mass, 56,624 Da) was identiﬁed in the
partially puriﬁed preparation. ERp57 (also known as ER-60, ERp60,
ERp61, GRP58) is a member of the protein-disulﬁde isomerase (PDI)
family and was originally found in the endoplasmic reticulum (ER) of
rat liver [25]. ERp57 has also been found in the cytosol [26] and
nucleus [27], and is involved in correcting the folding and rearranging
of the disulﬁde bond of misfolded glycoproteins [28,29]. ERp57 has
Fig. 1. SDS-PAGE, MALDI-TOFMS analysis of partially puriﬁed mitochondrial calpain.
SDS-PAGE silver staining. Lane M, molecular weight standards. Lane a, mitochondrial
IMS fraction (10 μg). Lane b, partially puriﬁed preparation of mitochondrial calpain
(2 μg). As shown in “Suplemental Data”, protein bands at about 50–80 kDawere excised
and subjected to the peptide mass ﬁngerprinting analysis (described in “Materials and
methods”). Twelve of 32 peptide masses matched with ERp57 of rats (MW 56,624) at a
coverage of 31% (open arrowhead).
Fig. 2. Mitochondrial localization of ERp57 and mitochondrial μ-calpain. Immunoblot
for anti-ERp57 in rat liver mitochondrial compartments. ERp57 exists in mitochondrial
compartments (5 μg/lane). Mitochondrial μ-calpain large and small subunits are also
mainly located in the IMS (20 μg/lane). The purity of the mitochondrial compartments
was determined with the appropriate antibody to marker protein [calnexin, ER mem-
brane; BiP, ER lumen; GAPDH, Cytosol; VDAC, OM; AK2, IMS; AIF, IM; PDH, Matrix]
(20 μg/lane). High purities of the mitochondrial compartments can be seen, therefore,
the possibility of a contamination of the mitochondrial fraction by ER fraction was
eliminated. Each fraction used is described in the “Materials and methods”.
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organization, and it was found that ERp57 functions as a molecular
chaperone within the ER [30–32]. It is also possible that ERp57 is
associated with mitochondrial μ-calpain. Thus, we examined the location
of ERp57 in the mitochondria by Western blots, and the interaction
between ERp57 and mitochondrial μ-calpain by immunoprecipitation,
nondenaturing PAGE, and casein zymography. We also examined this
interaction using several PDI inhibitors and anti-ERp57 antibody.
Mitochondria play an important role in initiating apoptosis, and
releasing apoptosis-related proteins into the cytoplasm that are
usually present in the intermembrane space (IMS) in the early stages
of apoptotic cell death [33]. Apoptosis-inducing factor (AIF), one of the
apoptosis-related proteins, is known to be a key factor of caspase-
independent apoptosis [34], and it functions as an anti-apoptotic
factor through its oxidoreductase activity [35]. We have shown that
mitochondrial calpain can degrade AIF to truncated AIF (tAIF), which
releases the tAIF from the mitochondrial inner membrane (IM) into
the IMS [23]. However, we have not tested which mitochondrial
calpain, mitochondrial μ-calpain, or unknown mitochondrial calpain,
is involved in this processing.
The purpose of this study was to determine whether ERp57 is
associated with mitochondrial μ-calpain, and whether ERp57-asso-
ciated mitochondrial μ-calpain plays a role in mitochondrial apoptotic
signaling by cleaving AIF.
2. Materials and methods
2.1. Subcellular fractionation
All of the procedures were carried out at 4 °C as described [23]. To obtain
mitochondrial μ-calpain, the mitochondrial IMS fraction of the liver was prepared from
20 Sprague–Dawley rats (8-weeks old). The rat liverswerewashedwith buffer A (20mM
Tris–HCl, pH 7.5, containing 1 mM EDTA, 1 mM EGTA, 0.25 M sucrose, and 5 mM 2-
mercaptoethanol) and homogenized in 1.5 l of buffer A. Mitochondrial and microsomal
fractionswere obtained by differential centrifugation andwerewashed three timeswith
buffer A. The fractions, except the supernatants, were centrifuged again under the same
conditions and resuspended in buffer B (20 mM Tris–HCl, pH 7.5, 1 mM EDTA, 1 mM
EGTA, and 5 mM 2-mercaptoethanol) containing 140 mM NaCl (buffer C). The cytosolic
fractions were dialyzed overnight against buffer C and used for Western blot analysis
and casein zymography. For theWesternblot analysis of ERp57, themicrosomal fractions
containing endoplasmic reticulum (ER) were used as a positive control.
2.2. Subfractionation of mitochondria
Mitochondrial compartments were prepared as reported by Parson et al. [36]. The
purity of the mitochondrial compartments was determined by immunoblot analysis;anti-glyceraldehyde phosphate dehydrogenase (GAPDH) antibody for cytosolic fraction,
anti-mitochondrial porin (VDAC) antibody for mitochondrial outer membrane (OM),
anti-adenylate kinase 2 (AK2) for intermembrane space (IMS), anti-AIF antibody for
inner membrane (IM), and anti-pyruvate dehydrogenase (PDH) antibody for matrix.
High purities of the mitochondrial compartments were found.
2.3. Partial puriﬁcation of mitochondrial calpain
Apartial puriﬁcationofmitochondrial calpainwas accomplishedby twodifferent column
chromatographic procedures; phenyl-sepharose followed by DEAE-sepharose CL-6B (Amer-
sham Pharmacia Biotech) column chromatography. All chromatographic procedures
were performed at 4 °C. The mitochondrial IMS fraction was treated with 1 M saturated
(NH4)2SO4 for 1 h at 4 °C, and then the sample was applied to the phenyl-sepharose column
(15×300 mm) pre-equilibrated with buffer B containing 1 M (NH4)2SO4. The column was
washedwith220mlofbufferBcontaining1M(NH4)2SO4, and then themitochondrial calpain
was elutedwith180ml of buffer B at aﬂowrateof 1.0ml/min. The fraction sizewas4ml/tube.
Aliquots (50 μl) of the fractions were used to assay for calpain activity which was measured
with Succ-Leu-Tyr-7-amino-4-methylcoumarin (Succ-Leu-Tyr-AMC; BACHEM, Bubendorf) as
described [23]. The fractions containing the mitochondrial calpain were dialyzed overnight
against 500 ml of buffer B containing 50 mM NaCl (buffer D) at 4 °C.
The dialysate was applied onto a DEAE-Sepharose CL-6B (26.4×400 mm) column
pre-equilibrated with buffer D at a ﬂow rate of 1.0 ml/min. Unbound proteins were
eluted with 500 ml of buffer D. Mitochondrial calpain was eluted with a linear gradient
of 50–300 mMNaCl in buffer B in a total volume of 1 l. The fraction size was 10 ml/tube.
Aliquots (50 μl) of the fractions were used to assay for calpain activity. Fractions
containing mitochondrial calpain were concentrated to approximately 4 ml with the
Amicon Diaﬂo apparatus using a PM-10 membrane (Millipore Co., Bedford, MA). The
concentrated sample was dialyzed overnight against 200 ml of buffer C at 4 °C.
The ﬁnal purity of the mitochondrial calpain was determined by SDS-polyacryla-
mide gel electrophoresis (SDS-PAGE) with 10% acrylamide gel according to Laemmli
[37]. After the electrophoresis, proteins were made visible with a silver staining kit
(Wako Pure Chemical Industries, Osaka, Japan). The protein concentration was
measured by the Lowry et al.method [38] with bovine serum albumin as the standard.
2.4. Antibodies and Inhibitors
Rabbit anti-ERp57 antiserumwasprepared against the 17-amino acidC-terminal peptide
(VIQEEKPKKKKKAQEDL) of human ERp57 as described [39]. This peptide was synthesized,
conjugated with keyhole limpet hemocyanin by usingm-maleimidebenzoyl-N-hydroxysuc-
cimide ester and injected into a rabbit. To avoid non-speciﬁc interactions, anti-ERp57
antiserum was afﬁnity-puriﬁed using AF-amino-toyopearl columns coupled with the
corresponding synthetic peptides. Rabbit anti-calnexin and anti-BiP antisera were obtained
as described [40]. Other antibodies purchased were: rabbit polyclonal antibodies against
calpain1 (μ-calpain large subunit) domain IV (SigmaAldrich Corp., St. Louis,MO), anti-calpain
2 (m-calpain large subunit) domain III (Chemicon International Inc., Temecula, CA), anti-
calpain small subunitdomainV (TriplePointBiologics, Inc., ForestGrove,OR), AIF (Abcam, Inc.,
Cambridge, MA), GAPDH (Santa Cruz Biotechnology Inc., CA), AK2 (Santa Cruz Biotechnology
Inc., CA), VDAC (Calbiochem, Cambridge, MA), PDH (Molecular Probes, Eugene, OR), and
Fig. 3. Casein zymogram and immunoblots for cytosolic and mitochondrial fractions.
(A) Casein zymogram for cytosolic μ-, m-, and mitochondrial calpains. Samples used were
rat liver cytosol (50 μg), mitochondrial IMS (100 μg), and matrix (100 μg). The cytosolic
fraction showed an upper band for μ-calpain and a lower band for m-calpain. Two active
bands were detected in the IMS (numbers 1 and 2) and matrix (numbers 3 and 4). These
bands in the IMS andmatrix had different mobilities from cytosolic μ- and m-calpains. (B)
Casein zymogram of calpeptin-treated mitochondrial calpain. Calpeptin inhibited the
enzymatic bands in IMS (numbers 1 and 2) andmatrix (numbers 3 and 4). (C)Western blot
analysis of caseinolytic active bands. Following zymography, the caseinolytic bands of each
sample were cut into two pieces, and the gel pieces were applied onto the SDS-PAGE and
immunoblotting. In order from top panel to bottom, antibodies used were anti-μ-calpain
large subunit, m-calpain large subunit, calpain small subunit, and ERp57 antibodies.
Cytosolic fraction, mitochondrial IMS, and matrix (20 μg) were used as positive controls.
Cytosolic μ-calpain and mitochondrial calpain numbers 1 and 3 (mitochondrial μ-calpain)
were stained with anti-μ-calpain large subunit antibody. Only cytosolic m-calpain is
stained with anti-m-calpain large subunit antibody. Every band contains calpain small
subunits. Interestingly,mitochondrialμ-calpain (numbers1 and3) is also stainedwithanti-
ERp57 antibody.
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UK). Protein disulﬁde isomerase (PDI) inhibitors, 5-5′-dithiobis-2-nitrobenzoic acid (DTNB),
phenylarsine oxide (PAO), and triiodothyronine (T3), and protease inhibitors (leupeptin,
chymostatin, pepstatin, O-phenanthrolin), were purchased from Sigma. Calpain inhibitors,
calpeptin and PD150606, were purchased from Calbiochem. The membrane-impermanent
DTNB forms disulﬁdes with thiol groups [41]. The PAO forms coordination bonds with the
vicinal thiols of the CXXCmotif of proteins, such as ERp57, through their As+3 [42]. T3weakly
inhibits PDI family members by binding to sites other than CXXC [43]. The thyroid hormone
T3 exerts several diverse biological actions; PDI is homologous with the T3 receptor, and
PDI has twoT3-binding sites one of which is a high afﬁnity site and the other is a low afﬁnity
site.
2.5. Western blots
Western blots were performed according to Towbin et al. [44]. After electrophoretic
transferring the proteins to a nitrocellulose membrane, the membranewas treated with10mM phosphate buffer, pH 7.4, 0.14 M NaCl, and 0.05% Tween 20 (TW-PBS) containing
0.05% bovine serum albumin and 1% goat serum for 2 h at room temperature. The
membrane was then incubated with the appropriate primary antibody and HRP-
conjugated secondary antibodies at 4 °C overnight. Immunoreactive signals were
developed with an ECLWestern blotting detection kit (Amersham Biosciences), and the
immunoreactive bands were quantiﬁed with a Luminescent Image Analyzer, LAS-3000
(Fujiﬁlm Co., Tokyo, Japan).
2.6. Protein identiﬁcation by MALDI-TOFMS
The protein bands on the silver stained gels were excised, and in-gel tryptic
digestion was carried out according to Hellman et al. [45] with slight modiﬁcations.
Protein bands were cut into pieces, and destained with 50 mM sodium thiosulfate and
15 mM potassium ferricyanide. After discarding the destaining solution, the gel pieces
were washed with water three times, and soaked in 25 mM ammonium bicarbonate
containing 50% acetonitrile. Then, the gel pieces were dried in vacuo, and rehydrated
with a reducing solution (0.1 M ammonium bicarbonate and 10 mM dithiothreitol) and
incubated for 45 min at 56 °C. The reducing solution was removed and the gels were
soaked in an alkylating solution (0.1 M ammonium bicarbonate containing 55 mM
iodoacetamide) for 30 min in the dark. The gel pieces were washed with water twice
and soaked sequentially in 25 mM ammonium bicarbonate containing 50% acetonitrile,
100% acetonitrile, 0.1 M ammonium bicarbonate, and 25 mM ammonium bicarbonate
containing 50% acetonitrile. The gel pieces were dried in vacuo, and then the proteins in
the gels were digested with a protease as follows: the dried gel pieces were rehydrated
with 0.1 M ammonium bicarbonate containing 0.01 μg/ml sequencing grade trypsin
(PROMEGA, Madison, WI), and incubated for 20 h at 37 °C. The tryptic fragments were
extracted by shaking with 25 mM ammonium bicarbonate containing 50% acetonitrile
for 15 min, and 5% triﬂuoroacetic acid containing 50% acetonitrile were added for
further extraction. The peptide solutions were pooled and concentrated with a cen-
trifugal concentrator.
The peptides were dissolved in aliquots of 0.1% triﬂuoroacetic acid, and the peptide
masses were measured by matrix-assisted laser desorption-ionization time-of-ﬂight
mass spectrometry (Voyager-DE RP, Applied Biosystems, Foster City, CA) over the m/z
range of 800 to 3000 using 2, 5-dihydroxybenzoic acid (DHB) as a matrix. The mass
spectrumwas calibrated externally with angiotensin I and adenocorticotropic hormone
fragment 18–39. Database queries were performed for the monoisotopic masses using
MS-Fit program (http://prospector.ucsf.edu) against Swiss-Prot database.
2.7. Zymography
Zymographic analysis was carried out according to Raser et al. [46] and Arthur et al.
[47]. Brieﬂy, 60 μl of each sample was diluted in 0.1 M Tris–HCl, pH 6.8 containing 20%
glycerol, 10 mM 2-mercaptoethanol, and 10 mM EDTA, and loaded onto 10%
polyacrylamide gel containing 1 mg/ml casein (Sigma). The electrophoretic run was
carried out for 2.5 h at 4 °C and 125 V using 25 mM Tris–HCl, pH 8.0 containing 125 mM
glycine, 1 mM EDTA, and 10 mM 2-mercaptoethanol. After the electrophoretic run, the
gels were incubated overnight at room temperature in calcium proteolysis buffer
(20 mM Tris–HCl, pH 7.4 containing 10 mM 2-mercaptoethanol and 20 mM CaCl2) or
noncalcium proteolysis buffer (20 mM Tris–HCl, pH 7.4 containing 10 mM 2-mer-
captoethanol, 5 mM EDTA, and 1 mM EGTA) with gentle shaking. The gels were stained
with Coomassie Brilliant Blue R-250 for 30 min and destained overnight.
2.8. Nondenaturing polyacrylamide gel electrophoresis (Native PAGE)
Nondenaturing polyacrylamide gel electrophoresis was carried out to analyze
protein–protein interactions according to the modiﬁed method of zymography [46,47].
We used 7.5% polyacrylamide gel without casein as a separating gel. The sample buffer
and electrode buffer were the same as used for zymography.
2.9. Immunoprecipitation
The IgG content of rabbit anti-ERp57 antiserum was measured by competitive
enzyme-linked immunosorbent assay according to Ishiguro et al. [48,49]. The control
used was 400 μg/ml normal rabbit IgG. The IgG content of the rabbit anti-ERp57
antiserum was 3.87 mg/ml (data not shown). The polyclonal antibody to ERp57 (0.2–
50 μg) and normal rabbit IgG (0.2–50 μg) were incubated with 31.8 μl (400 μg) sample of
mitochondrial IMS in a total volume of 100 μl of buffer C. After 2 h at 4 °C, excess protein
G-Sepharose 4 Fast Flow (Amersham Pharmacia Biotech) was added (10 μl) and
incubated for 18 h at 4 °C. Each sample was centrifuged at 12,000 rpm for 5 min at 4 °C.
Fifty microliters of the supernatant was used for the assay of calpain activity as
described above.
ForWestern blot analysis, the resulting pellets were washed six times with buffer C
and mixed with SDS-PAGE or Native PAGE sample buffer.
2.10. Determination of AIF cleavage by endogenous mitochondrial calpain
The mitochondrial fraction obtained from the liver of two Sprague–Dawley rats (8-
weeks old) was resuspended in 2 volumes of 20 mM potassium phosphate buffer
containing 0.2 mg/ml bovine serum albumin (Wako) at pH 7.4 and allowed to stand at
4 °C for 1 h in the presence or absence of 10 μM DTNB, 5 μM calpeptin and 10 μM
Fig. 4. Immunoprecipitation of mitochondrial μ-calpain by polyclonal antibody to ERp57. (A) Polyclonal antibody (0.2–50 μg) to ERp57 was incubated with 100 μl (400 μg) of
mitochondrial IMS fraction (see description under “Materials and methods”). When a precipitation had formed, these samples were centrifuged at 12,000 rpm for 5 min at 4 °C.
Eighty microliters of the supernatant obtained was used to assay for calpain activity using Succ-Leu-Tyr-AMC as a substrate. Approximately 75% of the calpain activity is precipitated
by polyclonal antibody to ERp57 (●). Normal rabbit IgG (0.2–50 μg) is used as a control (○). (B) Twenty-ﬁve microliters of the supernatant obtained by immunoprecipitation with
anti-ERp57 antibody (0, 5, 10, 20, 30, and 50 μg) were used for casein zymography. The intensity of active band of mitochondrial μ-calpain speciﬁcally decreases in an antibody-
dependent manner. Solid and open arrowheads indicate mitochondrial μ-calpain and unknown mitochondrial calpain, respectively. (C) The resulting pellets after centrifugation at
12,000 rpmwere subjected to Western blot analysis using anti-μ-calpain large subunit and calpain small subunit antibodies. Both mitochondrial μ-calpain large and small subunits
are co-precipitated with ERp57 in IgG volume-dependent manner. Solid and open arrowheads indicate 76 kDa mitochondrial μ-calpain large subunit and 26 kDa small subunit,
respectively. (D) Supernatants obtained by immunoprecipitationwith anti-ERp57 antibody were incubated at 37 °C for an hour with freshly prepared IM (40 μg/tube) in the presence
of 1 mM CaCl2. Then the released tAIF and remaining AIF were separated by centrifugation at 105,000 ×g for 30 min, and detected by immunoblotting. The amount of 57 kDa
released tAIF decreases prominently as shown in “Supernatant” (upper panel), and that of 62 kDa AIF increases slightly in an antibody volume-dependent manner as shown in
“Pellet” (lower panel).
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7.5 and 5 mM 2-mercaptoethanol) and CaCl2 (ﬁnal concentration, 1 mM) was added to
the samples and incubated at 37 °C for 1 h. After incubation, EGTA (ﬁnal concentration,
5 μM) was added to each sample. Subfractionation of the mitochondria was performed
as described [23]. Each IMS and IM fraction was separated by SDS-PAGE, and then the
proteolytic processing and release of AIF from the IM into the IMS were detected by
immunoblotting.
3. Results
To identify the proteins associated with the mitochondrial μ-
calpain, we partially puriﬁed mitochondrial μ-calpain from rat liver
mitochondrial IMS by column chromatographies. A single peak of
mitochondrial μ-calpain was obtained by phenyl sepharose column
chromatography (data not shown). The peak fractions were used for
further puriﬁcation by DEAE-Sepharose CL-6B column chromatogra-
phy (data not shown). From this, a single peak of calpain activity was
isolated. A 14.7-fold or 5.3% puriﬁcation of mitochondrial μ-calpain
was obtained in the ﬁnal recovery.SDS-PAGE was used to determine the purity of mitochondrial μ-
calpain (Fig.1). The two strong bands at about 50–80 kDawere excised
and subjected to peptide mass ﬁngerprinting (PMF) analysis. As
shown in the “Supplemental data”, eleven of the 32 peptide masses
matched rat ERp57 (MW 56,624) at a coverage of 27%, and the average
mass error was 152 ppm (open arrowhead). Eight of the 18 peptide
masses matched with rat propionyl-CoA carboxylase α-chain mito-
chondrial precursor (MW77,712) at a coverage of 14%, and the average
mass error was 124 ppm (solid arrowhead). Partially puriﬁed
mitochondrial μ-calpain was stained with anti-μ-calpain large subunit
(calpain 1) and calpain small subunit antibodies (data not shown).
Immunoblot analysis showed that ERp57 was present in mito-
chondrial compartments as well as in the ER and cytosolic fractions
(Fig. 2). Mitochondrial μ-calpain large and small subunits were mainly
located in the mitochondrial IMS. We searched for the protein of
ERp57 in the list of human mitochondrial and mitochondrial-
associated proteins [50] and conﬁrmed that ERp57 protein is located
in the mitochondria.
Fig. 5. Interaction between ERp57 andmitochondrial μ-calpain. The polyclonal antibody
(20 μg) to ERp57 was incubated with 100 μl (400 μg) of mitochondrial IMS fraction at
4 °C for 2 h. Then 10 μl of goat anti-rabbit IgG was added to each mixture, and incubated
at 4 °C for 18 h. The samples were centrifuged at 12,000 rpm for 5 min, and these pellets
were washed six times with buffer C. These pellets were resuspended in buffer C
containing ERp57 peptide (100 μg/ml) and incubated at 4 °C for 2 h. Then each sample
was centrifuged at 12,000 rpm for 5 min, and these supernatants were mixedwith SDS-
PAGE or Native PAGE sample buffer. (A) SDS-PAGE and Western blot analysis of ERp57-
mitochondrial μ-calpain complex. ERp57, mitochondrial μ-calpain large subunit, and its
regulatory small subunit are present in the immunoprecipitates. (B) Native PAGE and
Western blot analysis of ERp57-mitochondrial μ-calpain complex. ERp57, mitochondrial
μ-calpain large subunit, and its regulatory small subunit have the same mobilities in
nondenaturing polyacrylamide gel (open arrowhead).
Fig. 6. No effects of Ca2+ on ERp57-mitochondrial μ-calpain interaction. Mitochondrial
IMS and matrix fractions (50 μg/tube) in a total volume of 10 μl of buffer B containing
5 μM calpeptin were incubated with or without Ca2+ (ﬁnal conc. 1 mM) for 30 min at
25 °C. Each sample was mixed with sample buffer for Native PAGE and applied to
nondenaturing polyacrylamide gels (50 μg/lane). After electrophoresis, proteins were
electrophoretically transferred to nitrocellulose membrane. Then ERp57-mitochon-
drial μ-calpain complexes were detected using immunostaining techniques with anti-
ERp57, anti-calpain 1 and anti-calpain small subunit, respectively. ERp57, mitochon-
drial μ-calpain large subunit and its regulatory small subunit have the same mobilities
(indicated by solid arrowheads) regardless of Ca2+, therefore no dissociation of the
complex was induced by Ca2+. Gray and open arrowheads point to calpain small
subunit associated with unknown mitochondrial calpain as described in “Fig. 3” and
free calpain small subunit (?), respectively.
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that there was an interaction between ERp57 and mitochondrial μ-
calpain. Zymograms of the cytosolic fraction revealed an upper band
for μ-calpain and a lower band form-calpain (Fig. 3A). Two bandswere
also detected in the IMS (numbers 1 and 2) and the matrix (numbers 3
and 4). The mobilities of these active bands were different from those
for cytosolic μ- and m-calpains. Pretreatment with a calpain inhibitor,
calpeptin, blocked the proteolytic activity of numbers 1–4 in the IMS
and matrix compartments (Fig. 3B). These results demonstrated that
two types of mitochondrial calpain, which can degrade casein, were
present in the mitochondria.
Following zymography, the caseinolytic bands of each samplewere
cut into two pieces, and the gel pieces were applied onto the SDS-
PAGE and immunoblotting (Fig. 3C). Cytosolic μ-calpain and upper
mitochondrial calpains (numbers 1 and 3) were positive to anti-μ-
calpain large subunit antibody, however only cytosolic m-calpain was
stained by anti-m-calpain large subunit antibody. The lower mito-
chondrial calpains (numbers 2 and 4) were not stained with anti-m-calpain large subunit and anti-m-calpain large subunit antibodies.
Every caseinolytic band contained calpain small subunits. Interest-
ingly, only mitochondrial μ-calpain (numbers 1 and 3) was associated
with ERp57 as shown in the lower panel of Fig. 4C.
Mitochondrial calpainwas immunoprecipitated from the IMS with
anti-ERp57 antibody to conﬁrm the interaction between ERp57 and
mitochondrial μ-calpain as shown in Fig. 4. Normal rabbit IgGwas used
as a control. Approximately 75% of the calpain activitywas precipitated
by the polyclonal antibody to ERp57 (Fig. 4A), and the caseinolytic
bands of mitochondrial μ-calpain disappeared after it was immuno-
precipitated with anti-ERp57 antibody (Fig. 4B). Western blot analysis
showed that mitochondrial μ-calpain large and small subunits were
also precipitated with anti-ERp57 antibody (Fig. 4C). Each supernatant
after immunoprecipitation with different amounts of anti-ERp57
antibody (containing 25–100% mitochondrial calpain activities) was
added to freshly prepared IM. After Ca2+-incubation, the released tAIF
from the IM and the remaining AIF were separated by centrifugation
and made visible by immunoblotting (Fig. 4D). Proteolytic process-
ing and the release of AIF were blocked by immunoprecipitation of
mitochondrial μ-calpain as shown in “Supernatant” (Fig. 4D, upper
panel), and the remaining AIF in the IM was slightly recovered in
antibody volume- and calpain activity-dependentmanner as shown in
“Pellet” (Fig. 4D, lower panel).
To obtain additional information about the interaction between
ERp57 and mitochondrial μ-calpain, the complexes immunoprecipi-
tated by anti-ERp57 antibody were analyzed by Western blot using
SDS-PAGE and Native PAGE as shown in Fig. 5. The immunoprecipi-
tates were treated with ERp57 peptide (100 μg/ml) releasing the
complex. The released complex was mixed with SDS-PAGE or Native
PAGE sample buffer. The complex contained ERp57 and mitochondrial
μ-calpain large and small subunits (Fig. 5A). ERp57 and mitochon-
drial μ-calpain large and small subunits had the same mobilities in
nondenaturing gel (Fig. 5B). Therefore, thesemolecules appeared to be
associated and form a complex.
We next investigated the role of Ca2+ on the interaction between
ERp57 and mitochondrial μ-calpain in the presence of calpeptin
(Fig. 6). Themobilities of ERp57,mitochondrial μ-calpain large subunit,
Fig. 8. Truncation and release of AIF by ERp57-associated mitochondrial μ-calpain.
Details are described in the “Materials and methods”. The samples (20 μg/lane) were:
lane 1 in the absence of Ca2+; lane 2 in the presence of 1 mMCa2+; lane 3 in the presence
of 1 mMDTNB and Ca2+; lane 4 in the presence of 1 mM Ca2+ and 5 μM calpeptin; lane 5
in the presence of 1 mM Ca2+ and 10 μM PD150606. Lane 6 contains freshly prepared IM
in buffer C (20 μg/lane). A 57 kDa truncated AIF (tAIF) is detected in the presence of Ca2+
(lane 2 and 5), however, DTNB inhibits the truncation and release of AIF from IM (lane
3). Solid and open arrowheads point to 62 kDa intact AIF and 57 kDa released tAIF,
respectively.
Fig. 9. Polyclonal antibody to ERp57 inhibits active bands of ERp57-associated
mitochondrial μ-calpain. Each IMS fraction (100 μg) was incubatedwith different amounts
of anti-ERp57 antibody (0, 0.05, 0.2, 0.4, 0.5, and 0.6 μg) for 2 h at 4 °C, and subjected
to casein zymography (A). The same amount of normal rabbit IgG was used as a control
(B). The intensity of the caseinolytic active bands of mitochondrial μ-calpain decreased in
an antibody concentration-dependent manner. Solid and open arrowheads indicate
mitochondrial μ-calpain and unknown mitochondrial calpain, respectively.
Fig. 7. Proteolytic degradation of mitochondrial μ-calpain. Cytosolic, mitochondrial IMS,
and matrix (40 μg/tube) in buffer C containing 5 μM calpeptin were allowed to stand
for 5 min at 37 °C in the presence (+) or absence (−) of 1 mM DTNB, PAO and T3. Then
each sample was subjected to Western blot analysis with anti-μ-calpain large subunit
(A), calpain small subunit (B), and ERp57 (C) antibodies. Mitochondrial μ-calpain large
subunit is strongly and weakly degraded in the presence of DTNB and PAO, respectively,
but not T3 (A). These three PDI inhibitors have no effect on the egulatory small subunit
(B) and ERp57 (C).
1960 T. Ozaki et al. / Biochimica et Biophysica Acta 1783 (2008) 1955–1963and its regulatory small subunit did not change in the presence of Ca2+
in the nondenaturing gel. The complex did not dissociate upon the
addition of Ca2+.
To determine whether ERp57 plays a role in the stabilization of
mitochondrial μ-calpain, we measured the effect of several PDI in-
hibitors on the stability of mitochondrial μ-calpain (Fig. 7). Interest-
ingly, DTNB and PAO caused a degradation of mitochondrial μ-calpain
large subunit (Fig. 7A), and the degradation was strongly enhanced by
DTNB but not by T3. Mitochondrial μ-calpain small subunit and ERp57
were not affected by exposure to DTNB, PAO, and T3 (Fig. 7B and C).
The protective effects of several protease inhibitors, e.g., leupeptin
(cystein protease inhibitor), chymostatin (serine protease inhibitor),
pepstatin (acid protease inhibitor), and O-phenanthrolin (metallopro-
tease inhibitor), on the degradation of mitochondrial μ-calpain large
subunit were examined (data not shown). DTNB and PAO induced a
proteolytic degradation of mitochondrial μ-calpain large subunit
(Fig. 7A), and the degradation was completely blocked by leupeptin
and pepstatin. Nondenaturing PAGE analysis showed that the DTNB-
induced proteolytic degradation of mitochondrial μ-calpain large sub-
unit was not caused by a dissociation of the protein complex (data not
shown).
We tested whether the ERp57-associated mitochondrial μ-calpain
processing of AIF to tAIF released tAIF into the IMS. First, we
preincubated isolated mitochondria with DTNB, and then added
1 mM Ca2+ to the mitochondrial solution. After incubation, we col-
lected the IMS fraction as described above. Each IMS fraction wasseparated by SDS-PAGE, and then the proteolytic processing and
release of AIF from the IM into the IMS were examined by im-
munoblotting (Fig. 8). Proteolytic processing of AIF and release of
tAIF into the IMS occurred in the presence of Ca2+ and were comple-
tely blocked by calpeptin and the more speciﬁc calpain inhibitor,
PD150606. Interestingly, DTNB prevented the release of tAIF.
We pre-treated mitochondrial IMS with anti-ERp57 antibody, and
then each sample was subjected to casein zymography as shown in
1961T. Ozaki et al. / Biochimica et Biophysica Acta 1783 (2008) 1955–1963Fig. 9. The caseinolytic active bands of mitochondrial μ-calpain were
speciﬁcally decreased in an antibody volume-dependent manner
(Fig. 9A). No effects of normal rabbit IgG on the caseinolytic active
bands were observed (Fig. 9B).
4. Discussion
Our results demonstrated that ERp57 is associated with mitochon-
drial μ-calpain which may then stabilize the enzyme. Exposure of
ERp57 to PDI inhibitors, DTNB and PAO, resulted in a loss of stability of
mitochondrial μ-calpain large subunit, and resulted in the degradation
of mitochondrial μ-calpain large subunit by other proteases. ERp57-
associated mitochondrial μ-calpain cleaves and releases AIF from the
IM. We suggested earlier that a unique system of mitochondrial
calpains and regulatory molecules associated with mitochondrial
calpains were present in mitochondria because calpastatin was not
present in themitochondria [23]. Although Kar et al. recently reported
that calpastatin is located in pulmonary smooth muscle mitochon-
dria, other investigators of mitochondrial calpains have not found
calpastatin in the mitochondria [51,52]. Our results demonstrated that
the mitochondrial calpain system is different from the cytosolic
system, at least in reference to the associated proteins.
Most mitochondrial proteins, except for a few proteins of the IM
andmatrix, are encodedbynuclear genes and synthesized as precursor
proteins in the cytosol. The mitochondria contain an elaborate system
to take up these proteins from the cytosol, guide them to speciﬁc
intramitochondrial compartments, and ensure that they have the
proper conformation. Many factors take part in this process. Cytosolic
molecular chaperones (Hsp70; heat shock protein 70), importing and
sorting machinery in the mitochondrial OM and IM, e.g., translocase
in the outer membrane (TOM) and protein sorting and assembly
machinery (SAM). In addition, matrix processing peptidase (MPP) and
mitochondrial molecular chaperones (small TIM proteins in the IMS,
Hsp60-Hsp10 system in the matrix) [53–57]. Small TIM proteins act as
chaperone-like molecules to guide and transport hydrophobic pre-
cursors from the TOMcomplex to the TIM complex across the IMS [56].
Hsp60 and Hsp10 are involved in the refolding of the precursor
proteins in the matrix. The formation of native disulﬁde bonds in the
ER is complex, and only the PDI family members, such as ERp57,
catalyzes the rate-limiting steps in the folding pathwayof polypeptides
[28–32].
It has been shown that ERp57 plays a role in the translocation of the
peptides of the major histocompatibility complex (MHC) class I by
associatingwith a transporter associatedwith antigenprocessing (TAP)-
tapasin complex [58,59]. As in thismechanism, ERp57maybeassociated
with the importmachinery, suchas TOMand TIM, andbe involved in the
refolding and disulﬁde bonds formation of precursor proteins (poly-
peptides). We found that ERp57 existed predominantly in the
mitochondrial OM, and the protein form is clearly different from the
cytosolic form (Fig. 2). It appears that ERp57, mitochondrial μ-calpain
large and small subunits form complexes, and cytosolic μ- and m-
calpains do not associate with ERp57 (Figs. 3–5). PDI inhibitors, DTNB
and PAO, induced a loss of stability of mitochondrial μ-calpain large
subunit (Fig. 7). Considering these ﬁndings and the results of our study,
we suggest that ERp57 functions mainly in the refolding of the mito-
chondrial μ-calpain large subunit which is involved in the formation of
disulﬁde bonds to form functional conformations. Unfolded proteins
have surface-exposed hydrophobic parts, and molecular chaperones
recognize hydrophobic surfaces on the proteins, suggesting that ERp57
is associated with the hydrophobic amino sequence of mitochondrial
μ-calpain.
Very recently, Badugu et al. reported that the N-terminal of calpain 1
contains an amphipathic α-helical domain, and calpain small subunit 1
is imported into mitochondrial IMS by a piggyback import mechanism
with calpain 1. The N-terminal of calpain 1 was not processed following
mitochondrial import [19]. Herrmann et al. suggested that IMS proteinsrequire folding and the formation of disulﬁde bonds because of protein
oxidation in the IMS [60]. If the cytosolic μ-calpain reported by Badugu
et al. and mitochondrial μ-calpain, as shown in this report, are identical
molecules, ourﬁndings of an association of ERp57withmitochondrial μ-
calpain, are strongly supportive of their report [19], i.e., cytosolic μ-
calpain is imported intomitochondria and trapped in the organelle. The
association of mitochondrial μ-calpain with ERp57 may provide an
important clue in understanding the mitochondrial location of
mitochondrial μ-calpain. Our data suggest that the mitochondrial μ-
calpain precursor, or cytosolic μ-calpain, translocates into themitochon-
dria by an import machinery such as the TOM complex, and then is
trapped following refolding and formation of disulﬁde bonds by its
association with ERp57.
Many researchers have recently begun to pay attention toAIF, and it
is becoming increasingly apparent that AIF is involved in retinitis
pigmentosa which is a form of retinal degeneration resulting from rod
photoreceptor death leading to blindness [61]. Otera et al. [62] repor-
ted that AIF is synthesized as an ~67-kDa protein with an N-terminal
presequence of 101 residues. The mitochondrial AIF is ~62 kDa and is
the mature form in the healthy condition, and the size of AIF detected
in the cytoplasm under apoptotic condition is ~57 kDa. AIF is anchored
to the outer face of the IM thatmust be cleaved to becomea soluble and
apoptogenic protein (tAIF). As shown, endogenous ERp57-associated
mitochondrial μ-calpain is involved in the cleavage of mature AIF
(~62 kDa) and the release of tAIF (~57 kDa) from the IM to the IMS. This
suggests that endogenous ERp57-associated mitochondrial μ-calpain
is an initiator of mitochondrial apoptotic signaling in the inner
mitochondrial compartment. Recently, Cao et al. identiﬁed μ-calpain
as a direct activator of the AIF release in neuronal cultures challenged
by oxygen-glucose deprivation and in the rat model of transient global
ischemia [63]. They suggested that activated μ-calpain (from cytosolic
and/or mitochondrial origin) may translocate to the mitochondrial
inner membrane, leading to the truncation and release of AIF. In this
study, we showed that endogenous mitochondrial μ-calpain can
truncate AIF.
DTNB and PAO induced a proteolytic degradation of mitochondrial
μ-calpain large subunit but T3 could not (Fig. 7). These three PDI
inhibitors act as different mechanisms [64]. The membrane-imper-
manent DTNB forms disulﬁdes with thiol groups [41]. The PAO forms
coordination bonds through their As+3 with the vicinal thiols of the
CXXC motif of proteins such as ERp57 [42]. T3 weakly inhibits PDI
family members by binding to sites other than CXXC [43]. The thyroid
hormone T3 exerts several diverse biological actions; PDI is homo-
logous with the T3 receptor, and PDI has two T3-binding sites one of
which is a high afﬁnity site and the other is a low afﬁnity site. T3 does
not induce proteolytic degradation of mitochondrial μ-calpain as
shown in Fig. 7, suggesting that the high afﬁnity site of ERp57 with T3
is blocked by an association between ERp57 and mitochondrial μ-
calpain. However, DTNB is a PDI inhibitor and we cannot exclude the
possibility that this agent affects mitochondrial μ-calpain. DTNB is less
speciﬁc than PAO and T3, however, PAO seems to be a more speciﬁc
inhibitor of ERp57, because CXXC (PDI family speciﬁc motif) is not
present in calpain molecules. It is not likely that PAO affects the
calpain molecule, although PAO induced the degradation of mito-
chondrial μ-calpain large subunit (Fig. 7A). ERp57 consists of 4 thio-
redoxin-like domains, abb'a', where the a and a' domains contain
catalytic CGHC motifs and the b and b' domains are noncatalytic. The
crystalline structure of the bb' fragment of human ERp57 [65] has
revealed its primary site for interaction with the lectin-like chaper-
ones, calnexin and calreticulin. So we expect that mitochondrial μ-
calpain also interacts with ERp57 via the b and b' domains. These
results and informations suggest that PAO binds with a CGHC motif of
ERp57, and this binding prevents the function of ERp57 and induces
the unfolding/unstabilization of mitochondrial μ-calpain, then the
unfoldedmitochondrial μ-calpain is subjected to degradation by some
mitochondrial proteases.
1962 T. Ozaki et al. / Biochimica et Biophysica Acta 1783 (2008) 1955–1963Our results demonstrate that ERp57 associates with mitochondrial
μ-calpain.We also suggest that the ERp57-associatedmitochondrial μ-
calpain plays a signiﬁcant role inmitochondrial apoptotic signaling via
direct cleavage of AIF. ERp57 inhibitors have a therapeutic potential for
many disorders such as retinitis pigmentosa and ischemia-induced
apoptosis observed in several tissues.
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